Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3584]

ASCO 2021: Newly approved drug effective against lung cancer caused by genetic mutation

ASCO 2021: Newly approved drug effective against lung cancer caused by genetic mutation

Novel antibody drug wakes up the body's defence system in advanced-stage cancer

Novel antibody drug wakes up the body's defence system in advanced-stage cancer

Ageing impairs anti-tumour T-cell response via mitochondria dysfunction

Ageing impairs anti-tumour T-cell response via mitochondria dysfunction

ASCO 2021: No survival difference for frontline combination regimens in real world intermediate-risk and poor-risk clear cell RCC

ASCO 2021: No survival difference for frontline combination regimens in real world intermediate-risk and poor-risk...

ASCO 2021: Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma

ASCO 2021: Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma

ASCO 2021: Choice of first-line platinum regimen does not significantly impact efficacy of second-line immunotherapy in advanced bladder cancer

ASCO 2021: Choice of first-line platinum regimen does not significantly impact efficacy of second-line...

ASCO 2021: Post-surgery immunotherapy extends disease-free survival for select patients with kidney cancer

ASCO 2021: Post-surgery immunotherapy extends disease-free survival for select patients with kidney cancer

ASCO 2021: Both single and dual immunotherapy regimens offer improved overall survival for select patients with advanced oesophageal cancer

ASCO 2021: Both single and dual immunotherapy regimens offer improved overall survival for select patients with...

ASCO 2021: Addition of immunotherapy to standard of care first-line regimen delays disease progression in advanced nasopharyngeal carcinoma

ASCO 2021: Addition of immunotherapy to standard of care first-line regimen delays disease progression in advanced...

Immunotherapy after surgery reduces deadly relapse risk in advanced bladder cancer

Immunotherapy after surgery reduces deadly relapse risk in advanced bladder cancer

More from ecancer